Clinical Trials and Research News Weekly Roundup | USAMRDC Develops COVID-19 Vaccine Candidate SpFN

Oct 26, 2020 | Digital Media, Video, Weekly Roundup

TrialSite News Weekly Roundup

 

U.S. Army Medical Research and Development (USAMRDC) Develops COVID-19 Vaccine Candidate (SpFN) Now in Clinical Trials: U.S. Army Medical Research and Development (USAMRDC) announce the commencement of Phase 1 clinical trials soon for a novel vaccine designed to take on SARS-CoV-2, the virus behind the pandemic. First delivered via a press release on Oct. 14, Dr. Kayvon Modjarrad, Director of Emerging Infectious Diseases at USAMRDC’s Walter Reed Army Institute of Research (WRAIR), reports encouragement about this particular approach for this internally developed vaccine. HTTPS://WWW.TRIALSITENEWS.COM/U-S-ARMY-MEDICAL-RESEARCH-AND-DEVELOPMENT-USAMRDC-DEVELOPS-COVID-19-VACCINE-CANDIDATE-SPFN-NOW-IN-CLINICAL-TRIALS/ RLF-100
 
Expanded Access Program At Houston Methodist Hospital 9-Fold Increased Probability of Survival from Critical COVID-19: Patients with critical COVID-19 and respiratory failure treated with RLF-100™ (aviptadil) have a 9-fold increased probability of survival and recovery from respiratory failure than those patients only on the standard of care, reports Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTF) and NeuroRx, Inc. based on a recent summary of Expanded Access Protocol results from Houston Methodist Hospital. Thanks to the heroic work of Dr. Jihad Georges Youssef and team there in Houston, as well as this investigational drug, lives were saved. A separate randomized controlled Phase 2b/3 clinical trial, to be completed by November 2020, should offer more evidence whether RLF-100 exhibits the definitive results for FDA approval or emergency use authorization. HTTPS://WWW.TRIALSITENEWS.COM/RLF-100-EXPANDED-ACCESS-PROGRAM-AT-HOUSTON-METHODIST-HOSPITAL-9-FOLD-INCREASED-PROBABILITY-OF-SURVIVAL-FROM-CRITICAL-COVID-19/
 
MATH+ Protocol Includes Ivermectin Option for Prophylaxis and Early Treatment of COVID-19; Phase of Disease Key to Care: “MATH+” is the COVID-19 protocol by Dr. Paul Marik and the Front Line Covid-19 Critical Care Alliance (FLCCC), as previously reported by TrialSite. And while NIH is still recommending ivermectin be used only in clinical trials, the September 28 update to MATH+ includes this drug as described below. The protocol notes that it, “is our recommended approach to COVID-19 based on the best (and most recent) literature. This is a very dynamic situation; therefore, we will be updating the guideline as new information emerges.” Beginning with prophylaxis, or prevention, the protocol notes that a safe and effective “cocktail” of substances may prevent or mitigate COVID-19. For this purpose, Marik recommends melatonin, high-dose vitamin D3 (deficiency of which has been tied to increased risk of catching COVID-19 and worse outcomes), vitamin C, zinc, and famotidine. For post-exposure prophylaxis, home-treatment during the acute phase, and mildly symptomatic hospital patients, ivermectin is listed as an optional medication.
HTTPS://WWW.TRIALSITENEWS.COM/MATH-PROTOCOL-INCLUDES-IVERMECTIN-OPTION-FOR-PROPHYLAXIS-AND-EARLY-TREATMENT-OF-COVID-19-PHASE-OF-DISEASE-KEY-TO-CARE/
 
 

0 Comments

Pin It on Pinterest